Jubilant Launched Remdesivir in India for COVID-19 Treatment

Jubilant's 24-hour helpline will enhance access to JUBI-R during these pandemic times where timely access to the drug may prove critical to treatment outcomes.

In order to extend its accessibility to patients below the poverty level and to frontline paramedical staff, Jubilant Bhartia Foundation -- a not-for-profit organisation of Jubilant Group -- is launching programmes aimed toward the distribution of the drug.

In May, Jubilant entered into a non-exclusive contract with Gilead Sciences Inc that granted it the proper to register, manufacture and sell investigational drug Remdesivir in 127 countries including India.

Remdesivir is that the only anti-viral drug that has received emergency use authorisation by the US Food and Drug Administration for treatment of suspected or laboratory-confirmed COVID-19 in adults and youngsters hospitalised with severe disease.

"We have launched the merchandise at affordable prices and strive to form it available in sufficient quantities to satisfy the high demand for the drug within the Indian market and in other countries," said Chairman and director Shyam S Bhartia and Co-Chairman Hari S Bhartia.